SCHEDULE: Stonepine Capital Discloses 7.9% Stake in CNS Pharma

Stonepine Capital Management and affiliates report a 7.9% beneficial ownership stake in CNS Pharmaceuticals, Inc. as of December 31, 2025.

Summary

• Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico collectively beneficially own 48,827 shares of CNS Pharmaceuticals, Inc. Common Stock.
• This ownership represents 7.9% of the outstanding Common Stock, calculated based on 620,290 shares outstanding as of November 14, 2025.
• The reporting persons share both voting and dispositive power over all 48,827 shares.
• The filing is an Amendment No. 1 to a previous Schedule 13G statement.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of CNS Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a standard regulatory disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.

Positives

• A significant institutional holding by Stonepine Capital Management and its affiliates may signal confidence in CNS Pharmaceuticals, Inc. to the market.

Negatives

• The filing itself does not present any negative information; it is a disclosure of beneficial ownership.

Risks

• The Schedule 13G filing primarily discloses beneficial ownership and does not detail specific risks related to CNS Pharmaceuticals, Inc.'s operations or financial health.

Future Outlook

The Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding CNS Pharmaceuticals, Inc.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors holding more than 5% of a company's stock, indicating their passive investment intent. This filing provides transparency into the ownership structure of CNS Pharmaceuticals, Inc., a biopharmaceutical company, and reflects an institutional investor's position within the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
• Management: Awareness of a substantial shareholder group, though the filing states no intent to influence control.

Key Dates

Keywords

CNS Pharmaceuticals, Stonepine Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, SEC Filing, Equity Stake